These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2949584)

  • 21. [Antihypertensive effect and adverse effects of isradipine in patients with sever hypertension. Results of an open multicenter study].
    Burger KJ; Dehner R
    Arzneimittelforschung; 1996 Jun; 46(6):600-5. PubMed ID: 8767350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twice-daily pindolol and alprenolol in essential hypertension of moderate severity.
    Hartikainen M; Heikkilä J
    Ann Clin Res; 1976 Apr; 8(2):85-92. PubMed ID: 779590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antihypertensive effect of isradipine on blood pressure at rest and during exercise.
    Dvorák I; Blaha M; Nĕmcová H
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):144S-146S. PubMed ID: 1673616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isotonic and isometric responses of blood pressure and heart rate in mild to moderate hypertension with isradipine and propranolol.
    Cantor A; Cristal N
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S76-8. PubMed ID: 1695309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment.
    Lind L; Berne C; Pollare T; Lithell H
    J Intern Med; 1994 Jul; 236(1):37-42. PubMed ID: 8021571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Circadian antihypertensive effect of sustained-release isradipine in patients with essential hypertension in comparison to placebo].
    Burger KJ; Anlauf M
    Arzneimittelforschung; 1993 Sep; 43(9):958-62. PubMed ID: 8240458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An acute dose-response pharmacodynamic evaluation of orally administered isradipine (PN-200-110) in hypertensive patients.
    McMahon FG; Vargas R; Ryan JR; Miller H; Faraday S
    J Clin Pharmacol; 1988 Jul; 28(7):664-6. PubMed ID: 2975291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hypertension with dihydropyridine calcium antagonists and aspirin.
    Tison P; Ulicna L; Jakubovska Z; Oravcova J; Fetkovska N
    Blood Press Suppl; 1994; 1():57-60. PubMed ID: 8205303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term renal effects of isradipine, a calcium entry blocker, in essential hypertension.
    Persson B; Wysocki M; Andersson OK
    J Cardiovasc Pharmacol; 1989 Jul; 14(1):22-4. PubMed ID: 2475710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial.
    Lüscher TF; Waeber B
    J Cardiovasc Pharmacol; 1993 Feb; 21(2):305-9. PubMed ID: 7679166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter evaluation of the safety and efficacy of isradipine in hypertension. The Italian-Belgian Isradipine Study Group.
    Am J Med; 1989 Apr; 86(4A):94-7. PubMed ID: 2523664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study.
    Wide-Swensson DH; Ingemarsson I; Lunell NO; Forman A; Skajaa K; Lindberg B; Lindeberg S; Marsàl K; Andersson KE
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):872-8. PubMed ID: 7573260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension.
    Sundstedt CD; Rüegg PC; Keller A; Waite R
    Am J Med; 1989 Apr; 86(4A):98-102. PubMed ID: 2523665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isradipine in the treatment of mild-to-moderate hypertension. The Austrian Multicenter Isradipine cum Spirapril Study (AMICUS).
    Magometschnigg D
    Am J Hypertens; 1993 Mar; 6(3 Pt 2):49S-53S. PubMed ID: 8466726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability and efficacy of PN 200-110, a new calcium antagonist in patients with angina and coronary heart disease.
    Handler CE; Sowton E
    Eur J Clin Pharmacol; 1984; 27(4):415-7. PubMed ID: 6240405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemodynamic effects of PN 200-110 (isradipine) in congestive heart failure.
    Greenberg B; Siemienczuk D; Broudy D
    Am J Cardiol; 1987 Jan; 59(3):70B-74B. PubMed ID: 2949588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. The British Isradipine Hypertension Group.
    Am J Med; 1989 Apr; 86(4A):110-4. PubMed ID: 2523644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of pindolol and methyldopa on blood pressure and plasma norepinephrine.
    Winer N; Carter CH; Eddy H
    Am Heart J; 1982 Aug; 104(2 Pt 2):425-31. PubMed ID: 7048879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction between two calcium antagonists and two beta blockers in conscious rabbits: hemodynamic consequences of differing cardiodepressant properties.
    Hof RP
    Am J Cardiol; 1987 Jan; 59(3):43B-51B. PubMed ID: 2880495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.
    Floras JS; Jones JV; Hassan MO; Sleight P
    Br Med J (Clin Res Ed); 1982 Nov; 285(6352):1387-92. PubMed ID: 6814568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.